Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Swedish Orphan Biovitrum AB Confirms FY 2013 Guidance


Friday, 26 Apr 2013 02:00am EDT 

Swedish Orphan Biovitrum AB announced that its outlook for the fiscal year 2013 remains unchanged. The Company expects fiscal year 2013 total revenues in the range of between SEK 2,000 million and SEK 2,200 million. It also expects fiscal year 2013 gross margin in the range of between 57% and 59%. According to I/B/E/S Estimates, analysts on average are expecting the Company to report revenue of SEK 2,110.14 million for the fiscal year 2013. 

Company Quote

84.3
-0.4 -0.47%
11:29am EDT